摘要
目的:探讨clusterin蛋白表达与上皮性卵巢癌临床病理学参数和预后的关系。方法:应用免疫组织化学方法检测clusterin蛋白在10例正常卵巢,10例卵巢良性腺瘤和68例上皮性卵巢癌组织中的表达;结合上皮性卵巢癌患者的临床病理学和预后资料,分析它们之间的相关性。结果:本组10例正常卵巢和10例卵巢良性腺瘤组织均呈clusterin蛋白的阴性或低水平的表达;在68例上皮性卵巢癌中,36例(53%)肿瘤出现clusterin蛋白过度表达,而且clusterin蛋白表达与肿瘤的临床分期有显著的相关性(P<0.05),Clusterin蛋白过度表达明显地多见于临床晚期(Ⅲ-Ⅳ期)的卵巢癌。另外,上皮性卵巢癌中clustern蛋白表达与肿瘤的预后显著相关,Clusterin蛋白过度表达的卵巢癌患者的生存时间明显短于正常表达者(log-rank=4.108,P=0.043)。结论:上皮性卵巢癌组织中clusterin蛋白的过度表达可以作为临床评估该肿瘤预后的新分子标记物之一。
Objective：To investigate the the protein expression of clusterin as related to clinicopathologieal data and prognosis in patients with epithelial ovarian cancers （EOC）. Methods： Immunohistochemistry （IHC） was used to detect the protein expression of clusterin in 10 cases of normal ovary, 10 of benign ovarian adenoma and 68 of EOC. The results were studied for a possible correlation with elinieopathological data and prognosis in EOC patients. Results： In our study, negative or low-level expression of clusterin were shown in 10 cases of normal ovary and 10 of benign ovarian adenoma, while over-expression of clusterin was observed in 38 （52%） of 68 patients with epithelial ovarian cancers. There was a significant correlation between clusterin expression and clinical staging of the tumor （ P 〈 O. 05 ） , where over-expressed clusterin was more likely in tumors of advanced stages （ 11-IV ）. In addition, the expression of clusterin in ovarian cancer was evidently correlated with patient prognosis. The mean survival length was obviously shorter in EOC patients with over-expressed clusterin than in those with normal clusterin expression （log-rank = 4. 108, P = 0. 043 ）. Conclusion： The over-expression of clusterin in epithelial ovarian cancer tissues may be useful as a novel molecular markers in clinical evaluation of patient prognosis.
出处
《广州医学院学报》
2011年第4期9-12,共4页
Academic Journal of Guangzhou Medical College
基金
广东省科技计划(2004B35001004和2005A30801001)
国家自然科学基金(No.30772334)
